

Übersichtsartikel

Codlin, S; Mole, SE

S. pombe btn1, the orthologue of the Batten disease gene CLN3, is required for vacuole protein sorting of Cpy1p and Golgi exit of Vps10p.

Journal of Cell Science 122 (8): 1163-73, 2009

Codlin, S; Mole, SE

Btn1 affects endocytosis, polarization of sterol-rich membrane domains and polarized growth in Schizosaccharomyces pombe.

Traffic 9 (6): 936-50, 2008

Gachet, Y; Codlin, S; Hyams, JS; Mole, SE

Btn1, the Schizosaccharomyces pombe homologue of the human Batten disease gene CLN3, regulates vacuole homeostasis.

Journal of Cell Science 118 (23): 5525-36, 2005

Ballabio, A; Gieselmann, V

Lysosomal disorders: From storage to cellular damage.

Biochimica et Biophysica Acta – Molecular Cell Research 1793 (4): 684-96, 2009

Platt, FM; Lachmann, RH

Treating lysosomal storage disorders: Current practice and future prospects.

Biochimica et Biophysica Acta – Molecular Cell Research 1793 (4): 737-45, 2009

Macauley, SL; Sands, MS

Promising CNS-directed enzyme replacement therapy for lysosomal storage diseases.

Experimental Neurology 218 (1): 5-8, 2009

Sleat, DE; Ding, L; Wang, S; Zhao, CF; Wang, YH; Xin, WN; Zheng, HY; Moore, DF; Sims, KB; Lobel, P

Mass Spectrometry-based protein profiling to determine the cause of lysosomal storage diseases of unknown etiology.

Molecular & Cellular Proteomics 8 (7): 1708-18, 2009

Settembre, C; Fraldi, A; Jahreiss, L; Spampinato, C; Venturi, C; Medina, D; de Pablo, R; Tacchetti, C; Rubinsztein, DC; Ballabio, A

A block of autophagy in lysosomal storage disorders.

Human Molecular Genetics 17 (1): 119-29, 2008

Castaneda, JA; Lim, MJ; Cooper, JD; Pearce, DA

Immune system irregularities in lysosomal storage disorders.

Acta Neuropathologica 115 (2): 159-74, 2008

Mu, TW; Fowler, DM; Kelly, JW

Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis.

Plos Biology 6 (2): 253-65, 2008

Settembre, C; Fraldi, A; Rubinsztein, DC; Ballabio, A
Lysosomal storage diseases as disorders of autophagy.
Autophagy 4 (1): 113-4, 2008

Beck, M
New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy.
Human Genetics 121 (1): 1-22, 2007

Beck, M
Lysosomal storage disorders.
Monatsschrift Kinderheilkunde 155 (7): 653-61, 2007

Jabs, S; Quitsch, A; Kakela, R; Koch, B; Tynnela, J; Brade, H; Glatzel, M; Walkley, S; Saftig, P, Vabier, MT; Braulke, T
Accumulation of bis(monoacylglycero)phosphate and gangliosides in mouse models of neuronal ceroid lipofuscinosis.
Journal of Neurochemistry 106 (3): 1415-25, 2008

Seehafer, SS; Pearce, DA
You say lipofuscin, we say ceroid: Defining autofluorescent storage material.
Neurobiology of Aging 27 (4): 576-88, 2006

Cooper, JD; Russell, C; Mitchison, HM
Progress towards understanding disease mechanisms in small vertebrate models of neuronal ceroid lipofuscinosis.
Biochimica et Biophysica Acta – Molecular Basis of Disease 1762 (10): 873-89, 2006

Jalanko, A; Braulke, T
Neuronal ceroid lipofuscinoses.
Biochimica et Biophysica Acta – Molecular Cell Research 1793 (4): 697-709, 2009

Hobert, JA; Dawson, G
Neuronal ceroid lipofuscinoses therapeutic strategies: Past, present and future.
Biochimica et Biophysica Acta – Molecular Basis of Disease 1762 (10): 945-53, 2006

Kyttala, A; Lahtinen, U; Braulke, T; Hofmann, SL
Functional biology of the neuronal ceroid lipofuscinoses (NCL) proteins.
Biochimica et Biophysica Acta – Molecular Basis of Disease 1762 (10): 920-33, 2006

Adulte NCL

Gdynia, HJ; Sperfeld, AD; Ludolph, AC
Adult-onset neuronal ceroid lipofuscinosis.
Nervenarzt 78 (2): 139, 2007

Ramadan, H; Al-Din, AS; Ismail, A; Balen, F; Varma, A; Twomey, A; Watts, R; Jackson, M; Anderson, G; Green, E; Mole, SE

Adult neuronal ceroid lipofuscinosis caused by deficiency in palmitoyl protein thioesterase 1.

Neurology 68 (5): 387-8, 2007

CLN1 (infantile NCL)

Kielar, C; Maddox, L; Bible, E; Pontikis, CC; Macauley, SL; Griffey, MA; Wong, M; Sands, MS; Cooper, JD

Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis.

Neurobiology of Disease 25 (1): 150-62, 2007

Qiao, X; Lu, JY; Hofmann, SL

Gene expression profiling in a mouse model of infantile neuronal ceroid lipofuscinosis reveals upregulation of immediate early genes and mediators of the inflammatory response.

BMC Neurosciences 8 Art No. 95, 2007

Griffey, MA; Wozniak, D; Wong, M; Bible, E; Johnson, K; Rothman, SM; Wentz, AE; Cooper, JD; Sands, MS

CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis.

Molecular Therapy 13 (3): 538-47, 2006

Lei, B; Tullis, GE; Kirk, MD; Zhang, KQ; Katz, ML

Ocular phenotype in a mouse gene knockout model for infantile neuronal ceroid lipofuscinosis.

Journal of Neuroscience Research 84 (5): 1139-49, 2006

Lu, JY; Hofmann, SL

Inefficient cleavage of palmitoyl-protein thioesterase (PPT) substrates by aminothiols: Implications for treatment of infantile neuronal lipofuscinosis.

Journal of Inherited Metabolic Disease 29 (1): 119-26, 2006

CLN2 (spätinfantile NCL)

Worgall, S; Kekatpure, MV; Heier, L; Ballon, D; Dyke, JP; Shungu, D; Mao, X; Kosofsky, B; Kaplitt, MG; Souweidane, MM; Sondhi, D; Hackett, NR; Hollmann, C; Crystal, RG

Neurological deterioration in late infantile neuronal ceroid lipofuscinosis.

Neurology 69 (6): 521-35, 2007

Sleat, DE; El-Banna, M; Sohar, I; Kim, KH; Dobrenis, K; Walkley, SU; Lobel, P
Residual levels of tripeptidyl-peptidase I activity dramatically ameliorate disease in late-infantile neuronal ceroid lipofuscinosis.
Molecular Genetics and Metabolism 94 (2): 222-33, 2008

Worgall, S; Sondhi, D; Hackett, NR; Kosofsky, B; Kekatpure, MV; Neyzi, N; Dyke, JP; Ballon, D; Heier, L; Greenwald, BM; Christos, P; Mazumdar, M; Souweidane, MM; Kaplitt, MG; Crstal, RG
Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA.
Human Gene Therapy 19 (5): 463-74, 2008

Steiner, R; Koch, T; Al-Uzri, A; Uchida, N; Tamaki, S; Tsukamoto, A; Guillaume, D; Selden, N
A phase I clinical study of human CNS stem cells (HUCNS-SC) in patients with neuronal ceroid lipofuscinosis.
Molecular Genetics and Metabolism 92 (4): 17, 2007

Chang, M; Cooper, JD; Sleat, DE; Cheng, SH; Dodge, JC; Passini, MA; Lobel, P; Davidson, BL
Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis.
Molecular Therapy 16 (4): 649-56, 2008

Guhaniyogi, J; Sohar, I; Das, K; Stock, AM; Lobel, P
Crystal structure and autoactivation pathway of the precursor form of human tripeptidyl-peptidase 1, the enzyme deficient in late infantile ceroid lipofuscinosis.
Journal of Biological Chemistry 284 (6): 3985-97, 2009

Steinfeld, R; Pal, A; Grune, T; Kratzner, R; Gartner, J; Sheldrick, G
The structure of tripeptidyl peptidase I (TPP1) provides insight into the molecular basis of late infantile neuronal ceroid lipofuscinosis.
European Journal of Pediatrics 168 (3): 379-80, 2009

Pal, A; Kraetzner, R; Gruene, T; Grapp, M; Schreiber, K; Gronborg, M; Urlaub, H; Becker, S; Asif, AR; Gartner, J; Sheldrick, GM; Steinfeld, R
Structure of tripeptidyl-peptidase I provides insight into the molecular basis of late infantile neuronal ceroid lipofuscinosis.
Journal of Biological Chemistry 284 (6): 3976-84, 2009

Passini, MA; Dodge, JC; Bu, J; Yang, W; Zhao, Q; Sondhi, D; Hackett, NR; Kaminsky, SM; Mao, QW; Shihabuddin, LS; Cheng, SH; Sleat, DE; Stewart, GR; Davidson, BL; Lobel, P; Crystal, RG
Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis.
Journal of Neurosciences 26 (5): 1334-42, 2006

CLN3 (juvenile NCL)

Kitzmuller, C; Haines, RL; Codlin, S; Cutler, DF; Mole, SE

A function retained by the common mutant CLN3 protein is responsible for the late onset of juvenile neuronal ceroid lipofuscinosis.

Human Molecular Genetics 17 (2): 303-12, 2008

Chan, CH; Mitchison, HM; Pearse, DA

Transcript and in silico analysis of CLN3 in juvenile neuronal ceroid lipofuscinosis and associated mouse models.

Human Molecular Genetics 17 (21): 3332-39, 2008

Weimer, JM; Benedict, JW; Elshatory, YM; Short, DW; Ramirez-Montealegre, D; Ryan, DA; Alexander, NA; Federhoff, HJ; Cooper, JD; Pearce, DA

Alterations in striatal dopamine catabolism precede loss of substantia nigra neurons in a mouse model of juvenile neuronal ceroid lipofuscinosis.

Brain Research 116298-112, 2007

Herrmann, P; Druckrey-Fiskaaen, C; Kouznetsova, E; Heinitz, K; Bigl, M; Cotman, SL; Schliebs, R

Developmental impairments neurotransmitter systems in Cln3(Delta ex7/8) knock-in mice, an animal model of juvenile neuronal ceroid lipofuscinosis.

Journal of Neuroscience Research 86 (8): 1857-70, 2008

Adams, H; de Blicke, EA; Mink, JW; Marshall, FJ; Kwon, J; Dure, L; Rothberg, PG; Ramirez-Montealegre, D; Pearce, DA

Standardized assessment of behaviour and adaptive living skills in juvenile neuronal ceroid lipofuscinosis.

Developmental Medicine and Child Neurology 48 (4): 259-64, 2006

Aberg, L; Talling, M; Harkonen, T; Lonqvist, T; Knip, M; Alen, R; Rantala, H; Tyynela, J

Intermittent prednisolone and autoantibodies to GAD65 in juvenile neuronal ceroid lipofuscinosis.

Neurology 70 (14): 1218-20, 2008

Cao, Y; Espinola, JA; Fossale, E; Massey, AC; Cuervo, AM; MacDonald, ME; Cotman, SL

Autophagy is disrupted in a knock-in mouse model of juvenile neuronal ceroid lipofuscinosis.

Journal of Biological Chemistry 281 (29): 20483-20493, 2006

Hainsworth, DP; Liu, GT; Hamm, CW; Katz, ML

Funduscopy and angiographic appearance in the neuronal ceroid lipofuscinoses.

Retina – The Journal of Retinal and Vitreous Diseases 29 (5): 657-68, 2009

Weimer, JM; Benedict, JW; Getty, AL; Pontikis, CC; Lim, MJ; Cooper, JD; Pearce, DA

Cerebellar defects in a mouse model of juvenile neuronal ceroid lipofuscinosis.

Brain Research 126693-107, 2009

Lim, MJ; Beake, J; Bible, E; Curran, TM; Ramirez-Montealegre, D; Pearce, DA; Cooper, JD

Distinct patterns of serum immunoreactivity as evidence for multiple brain-directed autoantibodies in juvenile neuronal ceroid lipofuscinosis.

Neuropathology and Applied Neurobiology 32 (5): 469-82, 2006

Ruther, K; Gal, A; Kohlschutter, A

The role of the ophthalmologist in the management of juvenile neuronal ceroid lipofuscinosis – Juvenile neuronal ceroid lipofuscinosis.

Klinische Monatsblätter für Augenheilkunde 223 (6): 542-4, 2006

CLN5

Lebrun, AH; Storch, S; Kytalla, A; Mole, SE; Kohlschutter, A; Ullrich, K; Braulke, T; Schulz, A

Retention of lysosomal protein CLN5 in the endoplasmic reticulum causes neuronal ceroid lipofuscinosis in Asian sibship.

European Journal of Pediatrics 168 (3): 378, 2009

CLN6

Benedict, JW; Getty, AL; Wishart, TM; Gillingwater, TH; Pearce, DA

Protein Product of CLN6 Gene Responsible for Variant Late-Onset Infantile Neuronal Ceroid Lipofuscinosis Interacts with CRMP-2.

Journal of Neuroscience Research 87 (9): 2157-66, 2009

CLN7

Siintola, E; Topcu, M; Aula, N; Lohi, H; Minassian, BA; Paterson, AD; Liu, XQ; Wilson, C; Lahtinen, U; Anttonen, AK; Lehesjoki, AE

The novel neuronal ceroid lipofuscinosis gene MFSD8 encodes a putative lysosomal transporter.

American Journal of Human Genetics 81 (1): 136-46, 2007

CLN10

Steinfeld, R; Mole, SE; Niezen-de Boer, R; Gartner, J

The CLN10 subtype of neuronal ceroid lipofuscinosis is caused by mutations in the CTSD gene and is associated with a variable age of onset.

Journal of Inherited Metabolic Disease 30:93-93, 2007

Partanen, S; Haapanen, A; Kielar, C; Pontikis, C; Alexander, N; Inkinen, T; Saftig, P; Gillingwater, TH; Cooper, JD; Tyynela, J

Synaptic changes in the thalamocortical system of cathepsin D-deficient mice: A model of human congenital neuronal ceroid-lipofuscinosis.

Journal of Neuropathology and Experimental Neurology 67 (1); 16-29, 2008

Siintola, E; Partanen, S; Stromme, P; Haapanen, A; Haltia, M; Maehlen, J; Lehesjoki, AE; Tyynela, J

Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis.

Brain 129:1438-1445 Part 6, 2006

Klinik

Psychoorganisches Syndrom

Backman ML, Santavuori PR, Aberg LE, Aronen ET.

Psychiatric symptoms of children and adolescents with juvenile neuronal ceroid lipofuscinosis.

J Intellect Disabil Res. 2005 Jan; 49(Pt 1): 25-32.

Epilepsie

Vigevano F.

Levetiracetam in pediatrics.

J Child Neurol. 2005 Feb; 20(2): 87-93.

Gupta R, Appleton R.

Corticosteroids in the management of the paediatric epilepsies.

Arch Dis Child. 2005 Apr; 90(4): 379-84.

Lipofuszin

Terman A, Brunk UT.

Lipofuscin.

Int J Biochem Cell Biol. 2004 Aug; 36(8): 1400-4.

Keller JN, Dimayuga E, Chen Q, Thorpe J, Gee J, Ding Q.

Autophagy, proteasomes, lipofuscin, and oxidative stress in the aging brain.

Int J Biochem Cell Biol. 2004 Dec;36(12):2376-91.

Wolf G.

Lipofuscin and macular degeneration.

Nutr Rev. 2003 Oct; 61(10): 342-6.

Brunk UT, Terman A.

Lipofuscin: mechanisms of age-related accumulation and influence on cell function.

Free Radic Biol Med. 2002 Sep 1; 33(5): 611-9.

Lysosomale Speicherkrankheiten

Fabry

Banikazemi M, Ullman T, Desnick RJ.

Gastrointestinal manifestations of Fabry disease: Clinical response to enzyme replacement therapy.

Mol Genet Metab. 2005 Jun 3; [Epub ahead of print]

Schaefer E, Mehta A, Gal A.

Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey.

Acta Paediatr Suppl. 2005 Mar; 94(447): 87-92; discussion 79.

Banerjee TK.

Fabry disease with special reference to neurological manifestations.

Eur Rev Med Pharmacol Sci. 2004 Nov-Dec; 8(6): 275-81.

Gaucher

Jmoudiak M, Futerman AH.

Gaucher disease: pathological mechanisms and modern management.

Br J Haematol. 2005 Apr; 129(2): 178-88.

Andersson HC, Charrow J, Kaplan P, Mistry P, Pastores GM, Prakesh-Cheng A, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ; International Collaborative Gaucher Group U.S. Regional Coordinators.

Individualization of long-term enzyme replacement therapy for Gaucher disease.

Genet Med. 2005 Feb; 7(2): 105-10.

Sidransky E.

Gaucher disease: complexity in a "simple" disorder.

Mol Genet Metab. 2004 Sep-Oct; 83(1-2): 6-15.

Niemann-Pick

Li H, Repa JJ, Valasek MA, Beltroy EP, Turley SD, German DC, Dietschy JM.

Molecular, anatomical, and biochemical events associated with neurodegeneration in mice with Niemann-Pick type C disease.

J Neuropathol Exp Neurol. 2005 Apr; 64(4): 323-33.

Solomon D, Winkelman AC, Zee DS, Gray L, Buttner-Ennever J.
Niemann-pick type C disease in two affected sisters: ocular motor recordings and brain-stem neuropathology.

Ann N Y Acad Sci. 2005 Apr; 1039: 436-45.

Chang TY, Reid PC, Sugii S, Ohgami N, Cruz JC, Chang CC.

Niemann-pick type C disease and intracellular cholesterol trafficking.

J Biol Chem. 2005 Jun 3; 280(22): 20917-20. Epub 2005 Apr 14.

Pompe

Sun B, Zhang H, Franco LM, Brown T, Bird A, Schneider A, Koeberl DD.

Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter.

Mol Ther. 2005 Jun; 11(6): 889-98.

Klinge L, Straub V, Neudorf U, Schaper J, Bosbach T, Gorlinger K, Wallot M, Richards S,

Voit T.

Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.

Neuromuscul Disord. 2005 Jan; 15(1): 24-31.

Sandhoff

Hendriksz CJ, Corry PC, Wraith JE, Besley GT, Cooper A, Ferrie CD.

Juvenile Sandhoff disease--nine new cases and a review of the literature.

J Inherit Metab Dis. 2004; 27(2): 241-9.

Vergleichbare Symptomatiken

Alzheimer

Wisniewski T, Frangione B.

Immunological and anti-chaperone therapeutic approaches for Alzheimer disease.

Brain Pathol. 2005 Jan; 15(1): 72-7.

Bloom FE, Reilly JF, Redwine JM, Wu CC, Young WG, Morrison JH.

Mouse models of human neurodegenerative disorders: requirements for medication development.

Arch Neurol. 2005 Feb; 62(2): 185-7.

Wright AF.

Neurogenetics II: complex disorders.

J Neurol Neurosurg Psychiatry. 2005 May; 76(5): 623-31.

Bertram L, Tanzi RE.

The genetic epidemiology of neurodegenerative disease.

J Clin Invest. 2005 Jun; 115(6): 1449-57.

Snyder H, Wolozin B.

Pathological proteins in Parkinson's disease: focus on the proteasome.

J Mol Neurosci. 2004; 24(3): 425-42.

Zemke D, Majid A.

The potential of minocycline for neuroprotection in human neurologic disease.

Clin Neuropharmacol. 2004 Nov-Dec; 27(6): 293-8.

Weiner WJ.

Initial treatment of Parkinson disease: levodopa or dopamine agonists.

Arch Neurol. 2004 Dec; 61(12): 1966-9.

Stern MB.

Dopamine agonists modify the course of Parkinson disease.

Arch Neurol. 2004 Dec; 61(12): 1969-71.

Cl-Mutationen

Kasper D, Planells-Cases R, Fuhrmann JC, Scheel O, Zeitz O, Ruether K, Schmitt A, Poet M, Steinfeld R, Schweizer M, Kornak U, Jentsch TJ.

Loss of the chloride channel CLC-7 leads to lysosomal storage disease and neurodegeneration.

EMBO J. 2005 Mar 9;24(5): 1079-91.

Jentsch TJ, Poet M, Fuhrmann JC, Zdebik AA.

Physiological functions of CLC Cl- channels gleaned from human genetic disease

and mouse models.

Annu Rev Physiol. 2005; 67: 779-807.

Hubner CA, Jentsch TJ

Ion channel diseases.

Hum Mol Genet. 2002 Oct 1; 11(20): 2435-45.

Retinitis pigmentosa

Kalloniatis M, Fletcher EL.

Retinitis pigmentosa: understanding the clinical presentation, mechanisms and treatment options.

Clin Exp Optom. 2004 Mar; 87(2): 65-80.

Hims MM, Diager SP, Inglehearn CF.

Retinitis pigmentosa: genes, proteins and prospects.

Dev Ophthalmol. 2003; 37: 109-25.

Farrar GJ, Kenna PF, Humphries P.

On the genetics of retinitis pigmentosa and on mutation-independent approaches to therapeutic intervention.

EMBO J. 2002 Mar 1; 21(5): 857-64.

Therapieansätze

Eto Y, Shen JS, Meng XL, Ohashi T.

Treatment of lysosomal storage disorders: cell therapy and gene therapy.

J Inherit Metab Dis. 2004; 27(3): 411-5.

Desnick RJ.

Enzyme replacement and enhancement therapies for lysosomal diseases.

J Inherit Metab Dis. 2004; 27(3): 385-410.

Gentherapie

Harrower TP, Barker RA.

Is there a future for neural transplantation?

BioDrugs. 2004;18(3):141-53.

Patterson MC, Platt F.

Therapy of Niemann-Pick disease, type C.

Biochim Biophys Acta. 2004 Oct 11; 1685(1-3): 77-82.

Eberhardt O, Schulz JB.

Gene therapy in Parkinson's disease.

Cell Tissue Res. 2004 Oct; 318(1):243-60.

Rolling F.

Recombinant AAV-mediated gene transfer to the retina: gene therapy perspectives.

Gene Ther. 2004 Oct; 11 Suppl 1: S26-32.

Ioannou YA, Enriquez A, Benjamin C.

Gene therapy for lysosomal storage disorders.

Expert Opin Biol Ther. 2003 Aug; 3(5): 789-801.

Cheng SH, Smith AE.

Gene therapy progress and prospects: gene therapy of lysosomal storage disorders.

Gene Ther. 2003 Aug; 10(16): 1275-81.

D'Azzo A.

Gene transfer strategies for correction of lysosomal storage disorders.

Acta Haematol. 2003; 110(2-3): 71-85.

Bennett J.

Gene therapy for retinitis pigmentosa.

Curr Opin Mol Ther. 2000 Aug; 2(4): 420-5.

Stammzellen

Haruta M.

Embryonic stem cells: potential source for ocular repair.

Semin Ophthalmol. 2005 Jan-Mar; 20(1): 17-23.

Kim SU.

Human neural stem cells genetically modified for brain repair in neurological disorders.

Neuropathology. 2004 Sep; 24(3): 159-71.

Smith LE.

Bone marrow-derived stem cells preserve cone vision in retinitis pigmentosa.

J Clin Invest. 2004 Sep; 114(6): 755-7.

Otani A, Dorrell MI, Kinder K, Moreno SK, Nusinowitz S, Banin E, Heckenlively J, Friedlander M.

Rescue of retinal degeneration by intravitreally injected adult bone marrow-derived lineage-negative hematopoietic stem cells.

J Clin Invest. 2004 Sep; 114(6): 765-74.

Trans-splicing

Walsh CE.

New paradigms for gene transfer: RNA trans-splicing and small interfering RNA as therapeutic strategies.

Semin Hematol. 2004 Oct; 41(4): 297-302.

Pergolizzi RG, Crystal RG.

Genetic medicine at the RNA level: modifications of the genetic repertoire for therapeutic purposes by pre-mRNA trans-splicing.

C R Biol. 2004 Aug; 327(8): 695-709.

Mansfield SG, Chao H, Walsh CE.

RNA repair using spliceosome-mediated RNA trans-splicing.

Trends Mol Med. 2004 Jun; 10(6): 263-8.

Reich SJ, Auricchio A, Hildinger M, Glover E, Maguire AM, Wilson JM, Bennett J.

Efficient trans-splicing in the retina expands the utility of adeno-associated virus as a vector for gene therapy.

Hum Gene Ther. 2003 Jan 1; 14(1): 37-44.

Rogers CS, Vanoye CG, Sullenger BA, George AL Jr.

Functional repair of a mutant chloride channel using a trans-splicing ribozyme.

J Clin Invest. 2002 Dec; 110(12): 1783-9.

Substratentzug

Platt FM, Butters TD.

Substrate deprivation: a new therapeutic approach for the glycosphingolipid lysosomal storage diseases.

Expert Rev Mol Med. 2000 Feb 1; 2000: 1-17.

Liu Y, Wada R, Kawai H, Sango K, Deng C, Tai T, McDonald MP, Araujo K, Crawley JN, Bierfreund U, Sandhoff K, Suzuki K, Proia RL.

A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder.

J Clin Invest. 1999 Feb; 103(4): 497-505.